EPISODE · Apr 21, 2026 · 1 MIN
T-DXd Tolerability in Community-Treated HER2-Low Metastatic Breast Cancer: What Real-World Practice Is Showing
from TheBrief.Health · host TheBrief.Health
Trastuzumab Deruxtecan is becoming standard for HER2-low metastatic breast cancer, with safe community use requiring careful monitoring, patient education, and early management of serious lung-related side effects.
What this episode covers
Trastuzumab Deruxtecan is becoming standard for HER2-low metastatic breast cancer, with safe community use requiring careful monitoring, patient education, and early management of serious lung-related side effects.
NOW PLAYING
T-DXd Tolerability in Community-Treated HER2-Low Metastatic Breast Cancer: What Real-World Practice Is Showing
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m